Stefan Sandström is CEO of Biosector, a Japan‑based commercialisation specialist for life sciences. For nearly two decades in Japan, he has helped non‑Japanese companies establish and scale with Japan’s pharma/biopharma industries. He has facilitated business with 32 of Japan’s largest pharmaceutical companies. His focus is on “what is next for the industry” and applied, auditable AI that shortens cycle time and improves right‑first‑time. A frequent speaker at CGT and bioprocess meetings, he blends training in chemical engineering and medicine with hands‑on go‑to‑market execution to make advanced therapies manufacturable and accessible. Originally from Sweden, he lives in the Tokyo–Yokohama area and works across Asia, Europe, and North America to help companies convert scientific breakthroughs into dependable patient access.